阿戈美拉汀治疗抑郁症的研究进展(7)
[45] 陈晓刚,毛智群,周德祥,等.阿戈美拉汀治療抑郁症及其对患者性功能的影响[J].临床医药文献电子杂志,2018,5(90):14-15,17.
[46] 陈圣丽,黄兹高,洪亮,等.阿戈美拉汀与米氮平治疗抑郁症伴睡眠障碍的疗效比较[J].西南国防医药,2018,28(4):375-377.
[47] 杨志,迟强,栾中山.阿戈美拉汀与文拉法辛治疗抑郁症的临床对照研究[J].神经损伤与功能重建,2015,10(4):356-357.
[48] 任智勇,王斌红.阿戈美拉汀与度洛西汀治疗首发抑郁症患者的比较研究[J].中国药物与临床,2018,18(11):1995- 1997.
[49] MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY. Agomelatine(valdoxan/thymanax):risk of dose-related hepatotoxicity and liver failure-updated warnings and monitoring guidance[EB/OL].(2012-10- 30)[2019-01-12].http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199558.
[50] 国家食品药品监督管理局药品评价中心.药物警戒快讯:法国加强阿戈美拉汀的肝损害风险管理[EB/OL].(2013-12-23)[2019-01-12].http://www.cdr.gov.cn/jjkx 258/ywjjkx/2013/201312/t201312247450.html.
[51] EUROPEAN MEDICINES AGENCY. EMA confirms positive benefit-risk for antidepressant valdoxan/thymanax(agomelatine)[EB/OL].(2014-09-26)[2019-01-12].http://www.ema.europa.eu/docs/enGB/document library/Press release/2014/09/WC500173636.pdf.
[52] DE BERARDIS D,FORNARO M,SERRONI N,et al.Agomelatine beyond borders:current evidences of its efficacy in disorders other than major depression[J]. Int J Mol Sci,2015,16(1):1111-1130.
(收稿日期:2019-02-26 修回日期:2019-05-29)
(编辑:唐晓莲), 百拇医药(翟倩 丰雷 张国富 刘敏 王晶晶)
[46] 陈圣丽,黄兹高,洪亮,等.阿戈美拉汀与米氮平治疗抑郁症伴睡眠障碍的疗效比较[J].西南国防医药,2018,28(4):375-377.
[47] 杨志,迟强,栾中山.阿戈美拉汀与文拉法辛治疗抑郁症的临床对照研究[J].神经损伤与功能重建,2015,10(4):356-357.
[48] 任智勇,王斌红.阿戈美拉汀与度洛西汀治疗首发抑郁症患者的比较研究[J].中国药物与临床,2018,18(11):1995- 1997.
[49] MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY. Agomelatine(valdoxan/thymanax):risk of dose-related hepatotoxicity and liver failure-updated warnings and monitoring guidance[EB/OL].(2012-10- 30)[2019-01-12].http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON199558.
[50] 国家食品药品监督管理局药品评价中心.药物警戒快讯:法国加强阿戈美拉汀的肝损害风险管理[EB/OL].(2013-12-23)[2019-01-12].http://www.cdr.gov.cn/jjkx 258/ywjjkx/2013/201312/t201312247450.html.
[51] EUROPEAN MEDICINES AGENCY. EMA confirms positive benefit-risk for antidepressant valdoxan/thymanax(agomelatine)[EB/OL].(2014-09-26)[2019-01-12].http://www.ema.europa.eu/docs/enGB/document library/Press release/2014/09/WC500173636.pdf.
[52] DE BERARDIS D,FORNARO M,SERRONI N,et al.Agomelatine beyond borders:current evidences of its efficacy in disorders other than major depression[J]. Int J Mol Sci,2015,16(1):1111-1130.
(收稿日期:2019-02-26 修回日期:2019-05-29)
(编辑:唐晓莲), 百拇医药(翟倩 丰雷 张国富 刘敏 王晶晶)